Business Context and Reporting Period
This Form 8-K is a current report filed by Crinetics Pharmaceuticals, Inc. on March 17, 2026. The filing discloses a material event regarding the departure of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
Executive Departure: Jeff Knight has resigned as Chief Development and Operating Officer, effective on or about April 10, 2026.
- Reason: Mr. Knight is resigning to pursue another opportunity.
- Disagreement: The resignation is not related to any disagreement with the Company regarding operations, policies, or practices.
- Transition: All managerial responsibilities and direct reports will be reassigned to other members of the executive leadership team.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or specific risk factors beyond the standard disclosure of the executive departure. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Confirm the specific timeline for the reassignment of Mr. Knight's responsibilities.
- Monitor subsequent filings for the appointment of a permanent replacement for the Chief Development and Operating Officer role.
- Review the Company's pipeline status to assess the impact of this leadership change on drug development timelines.